AK-CLRN1

**AK-CLRN1** is an investigational gene therapy being developed for the treatment of Usher syndrome type IIIA, a rare autosomal recessive disorder characterized by progressive loss of both hearing and vision. The therapy is designed to deliver a functional copy of the CLRN1 gene, which encodes the clarin 1 protein crucial for normal function of cochlear hair cells and photoreceptors, using an adeno-associated virus (AAV) vector. By restoring clarin 1 function, AK-CLRN1 aims to halt or reverse the progression of sensory deficits in patients with Usher syndrome type IIIA. The developer is Akouos, which is now a subsidiary of Eli Lilly. As of the latest available information, AK-CLRN1 is in preclinical development and has not yet entered clinical trials[3][8][10][13].